Table 3. Observed Frequencies of DecisionDx-Melanoma Test Results in Patients With Localized Cutaneous Melanoma Stratified by American Joint Committee on Cancer Stage.
| Group | Patients, No. (%)a | |
|---|---|---|
| Recurrence | No recurrence | |
| Stage I melanoma (n = 623)26,27,28,29 | ||
| Class 1 | 15 (2) | 541 (87) |
| Class 2 | 6 (1) | 61 (10) |
| Stage II melanoma (n = 212)26,27,28,29 | ||
| Class 1 | 13 (6) | 62 (29) |
| Class 2 | 59 (28) | 78 (37) |
| Stage I-II melanoma (n = 1117)25,26,27,28,29 | ||
| Class 1 | 31 (3) | 824 (74) |
| Class 2 | 76 (7) | 186 (17) |
| Stage I-II melanoma with known stage of disease and melanoma recurrence outcome data (n = 835)26,27,28,29,b | ||
| Stage I | 21 (3) | 602 (72) |
| Stage II | 72 (9) | 140 (17) |
a
Percentages may not sum to 100 owing to rounding.
b
Data unavailable by stage for the patients in the study by Hsueh et al.25